Penserra Capital Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Penserra Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $32,847 - $59,179	1,593 Added 52.08%	4,652 $122,000
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $13,630 - $20,520	-580 Reduced 15.94%	3,059 $107,000
Q4 2021 Feb 15, 2022	SELL	$29.21 - $44.64 $19,862 - $30,355	-680 Reduced 15.74%	3,639 $117,000
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $94,075 - $171,911	-4,425 Reduced 50.61%	4,319 $127,000
Q2 2021 Aug 12, 2021	SELL	$12.56 - $29.69 $75,586 - $178,674	-6,018 Reduced 40.77%	8,744 $224,000
Q1 2021 May 13, 2021	SELL	$12.37 - $17.74 $85,835 - $123,097	-6,939 Reduced 31.98%	14,762 $202,000
Q4 2020 Feb 12, 2021	BUY	$9.82 - $18.27 $213,103 - $396,477	21,701 New	21,701 $359,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.